Residency · Residency · Radiation Oncology

Post-Mastectomy Radiation Therapy: Indications and Chest Wall Technique

Overview

Post-mastectomy radiation therapy (PMRT) plays a crucial role in reducing locoregional recurrence and improving overall survival in patients with high-risk breast cancer. Traditionally, PMRT has been indicated for patients with T3 or T4 tumors, those with four or more positive axillary lymph nodes, and cases with positive surgical margins. More recently, the indications have evolved to include patients with one to three positive lymph nodes, where the absolute benefit is smaller but nonetheless significant. The typical target volumes for PMRT encompass the chest wall and regional lymph nodes, including the supraclavicular, internal mammary, and axillary nodes. A critical consideration in treatment planning is cardiac avoidance, especially for left-sided tumors, to minimize radiation exposure to the heart.

Indications for PMRT

Established Indications (Strong Evidence)

Strong evidence supports PMRT for patients with four or more positive axillary lymph nodes, as well as those with large primary tumors classified as T3 (greater than 5 cm) or T4, regardless of nodal status. PMRT is also indicated for patients with positive surgical margins following mastectomy, inflammatory breast cancer (T4d), and tumors exhibiting skin or chest wall invasion (T4a-c).

1-3 Positive Lymph Nodes (Evolving Evidence)

The 2014 meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) demonstrated that PMRT reduces locoregional recurrence and breast cancer mortality in patients with one to three positive lymph nodes. Specifically, there was an absolute reduction in any recurrence at 10 years by 10.6% (from 45.7% to 35.1%) and an 8.1% absolute reduction in breast cancer mortality at 20 years. The magnitude of benefit depends on the baseline risk; patients with additional risk factors such as young age, lymphovascular invasion (LVI), high tumor grade, or estrogen receptor (ER)-negative status derive greater benefit from PMRT. The SUPREMO trial, which randomized intermediate-risk patients (those with one to three positive nodes or high-risk T2N0 disease) to PMRT versus no PMRT, is ongoing and will provide more definitive guidance. Currently, PMRT is recommended for most patients with one to three positive nodes, particularly when additional risk factors are present.

Node-Negative Disease

PMRT is not routinely indicated for node-negative (pN0) disease after mastectomy. However, it may be considered in patients with T3N0 tumors, especially if they are younger than 50 years, have lymphovascular invasion, high-grade tumors, or close surgical margins, although this remains controversial. Generally, the risk of chest wall recurrence is less than 10% for patients with pT1-2N0 disease after mastectomy.

PMRT After Neoadjuvant Chemotherapy

Current Recommendations

When PMRT is considered after neoadjuvant chemotherapy (NAC), radiation decisions should be based on the worst-case scenario, taking into account both the pre-chemotherapy clinical stage and the post-chemotherapy pathologic stage. If the pre-NAC stage would have warranted PMRT—such as clinical T3-4 tumors or clinical N1-3 nodal involvement—PMRT is recommended regardless of the pathologic response. The role of PMRT in patients who achieve a pathologic complete response (pCR) after NAC remains controversial.

Ongoing Trials

Several trials are investigating PMRT strategies after NAC. The NSABP B-51/RTOG 1304 trial is evaluating the omission of regional nodal irradiation in patients initially staged as cN1 who convert to ypN0 after NAC. The Alliance A011202 trial is examining the role of axillary radiation versus axillary lymph node dissection. Additionally, the NRG-BR007 trial is assessing the omission of PMRT in patients with pCR after NAC for initial cT1-3N1 disease.

Radiation Therapy Technique

Target Volumes

The clinical target volume (CTV) for the chest wall includes the ipsilateral chest wall, encompassing the mastectomy scar, surgical clips, and drain sites. Its boundaries are defined superiorly by the clavicular head or the match line with the supraclavicular field, inferiorly extending 1 to 2 cm below the contralateral inframammary fold, medially to the midline or sternal edge, laterally to the mid-axillary line, and deep to the anterior surface of the ribs and intercostal muscles, including the pectoralis muscles or their remnants. The supraclavicular and infraclavicular nodal CTV covers level III and the supraclavicular fossa. The axillary CTV includes levels I and II if these have not been fully dissected, as well as level III. The internal mammary nodal CTV encompasses the first three intercostal spaces along the internal mammary vessels, typically within 5 cm of the midline.

Dose and Fractionation

Conventional PMRT is delivered as 50 Gy in 25 fractions. Hypofractionated regimens, such as 40 Gy in 15 fractions or 42.56 Gy in 16 fractions, are increasingly used. Wang et al. (2019) demonstrated that hypofractionated PMRT (43.5 Gy in 15 fractions) is non-inferior to conventional fractionation. The FAST-Forward trial included some PMRT patients and is investigating ultra-hypofractionation with 26 Gy in 5 fractions. A chest wall boost of 10 to 16 Gy in 5 to 8 fractions may be delivered to the scar or drain sites, particularly for close or positive margins or inflammatory breast cancer.

Bolus

A chest wall bolus, typically 0.5 to 1.0 cm thick, is applied to the skin surface to increase the skin dose. It is indicated in cases of skin involvement, close skin margins, inflammatory breast cancer, or dermal lymphatic invasion. Common practice involves applying the bolus on alternate days or daily during the initial portion of treatment, such as the first half of the fractions. While bolus use improves skin dose coverage, it also increases the risk of acute skin toxicity, including moist desquamation. Therefore, clinicians must balance adequate skin dosing against the potential for toxicity. Some institutions apply bolus routinely for all PMRT patients, whereas others reserve it for those with high-risk skin features.

Beam Arrangements

Tangential fields are used to cover the chest wall with medial and lateral tangent beams, similar to whole breast irradiation geometry. Partially wide tangents are angled to include internal mammary nodes within the tangent fields, which reduces cardiac dose compared to using a separate internal mammary node field. The supraclavicular and axillary nodes are treated with an anterior oblique beam, typically anteroposterior (AP) or AP/posterior-anterior (PA), matched to the superior border of the tangent fields. Intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are increasingly employed for comprehensive nodal coverage, offering improved dose homogeneity and cardiac sparing. Mixed photon and electron techniques, such as an electron chest wall field combined with a photon supraclavicular field, are less common with the advent of modern IMRT.

Reconstruction Considerations

Radiation therapy in patients with tissue expander or implant reconstruction increases the risk of capsular contracture, which occurs in 30 to 50% of cases, as well as implant failure and the need for revision surgery. Autologous flap reconstructions, such as transverse rectus abdominis myocutaneous (TRAM), deep inferior epigastric perforator (DIEP), or latissimus dorsi flaps, generally tolerate radiation better, although fat necrosis and fibrosis can still occur. Timing of reconstruction is important; delayed reconstruction after PMRT may reduce radiation-related complications to the reconstruction, but immediate reconstruction with planned PMRT is common practice. Treatment planning must consider bolus use, dose homogeneity across the reconstructed chest wall, and the geometry of implants or expanders to optimize plan quality.

Cardiac Avoidance

Importance

Left-sided PMRT is associated with increased cardiac dose compared to breast-conserving radiation therapy due to the closer proximity of the chest wall to the heart. Internal mammary nodal irradiation further elevates cardiac exposure. Deep inspiration breath hold (DIBH) is the primary technique employed to reduce cardiac dose. The goal is to maintain a mean heart dose below 4 Gy and to minimize the maximum dose to the left anterior descending (LAD) coronary artery as much as possible.

Techniques

DIBH increases the distance between the heart and chest wall by 1 to 2 cm during inspiration, reducing the mean heart dose by 30 to 60%. IMRT and VMAT with cardiac optimization further improve cardiac sparing. Proton therapy can eliminate exit dose through the heart when treating the chest wall and regional nodes and is considered for patients at high cardiac risk with left-sided tumors requiring comprehensive nodal coverage.

<image>An illustration of the chest wall and regional nodal target volumes for PMRT on an axial CT cross-section. The chest wall CTV (red) is outlined along the anterior rib surfaces, including the pectoralis muscle remnant. The internal mammary nodal CTV (yellow) is shown surrounding the internal mammary vessels in the first 3 intercostal spaces. The supraclavicular CTV (green) is shown on a coronal view inset. Key organs at risk (heart, LAD, ipsilateral lung) are contoured with dose constraint values annotated.</image>

<image>A side-by-side comparison of dose distributions for left-sided PMRT with regional nodal irradiation: (A) free-breathing 3D-CRT with wide tangent fields, (B) DIBH with 3D-CRT, and (C) VMAT with DIBH. Mean heart dose, LAD max dose, V20 lung, and target coverage (V95%) are tabulated below each panel, demonstrating progressive improvement in cardiac sparing from technique A to C.</image>

<image>A clinical decision algorithm flowchart for PMRT indications. Starting node: "Post-mastectomy pathology." First branch: ">=4 positive nodes or T3/T4 or positive margins or inflammatory" leads to "PMRT recommended (strong evidence)." Second branch: "1-3 positive nodes" leads to "PMRT recommended for most patients, especially with additional risk factors (young age, LVI, high-grade, ER-negative)." Third branch: "Node-negative, T1-T2, negative margins" leads to "PMRT generally NOT indicated; consider for high-risk T2 features." A separate pathway addresses post-NAC decisions based on pre-treatment clinical stage.</image>

Key Clinical Pearls

The EBCTCG meta-analysis firmly established that PMRT reduces locoregional recurrence and improves breast cancer mortality even in patients with only one to three positive lymph nodes, although the absolute benefit depends on the baseline risk of recurrence. For patients receiving neoadjuvant chemotherapy, radiation decisions should be guided by the pre-NAC clinical stage; if the pre-NAC stage would have warranted PMRT, it should be delivered regardless of the pathologic response. The use of bolus on the chest wall is not universally required and should be reserved for patients with skin involvement, close skin margins, or inflammatory breast cancer, with close monitoring for moist desquamation. Hypofractionated PMRT regimens delivering 40 to 43.5 Gy in 15 to 16 fractions have been shown to be non-inferior to conventional fractionation and are increasingly adopted in clinical practice. Ultra-hypofractionation for PMRT is currently under investigation. For left-sided tumors, DIBH is considered the minimum standard for cardiac sparing, with IMRT/VMAT incorporating cardiac optimization and proton therapy serving as additional options for patients at elevated cardiac risk.

References

• EBCTCG. "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials." Lancet. 2014;383(9935):2127-2135.
• Overgaard M et al. "Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial." N Engl J Med. 1997;337(14):949-955.
• Ragaz J et al. "Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial." J Natl Cancer Inst. 2005;97(2):116-126.
• Wang SL et al. "Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial." Lancet Oncol. 2019;20(3):352-360.
• Recht A et al. "Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update." J Clin Oncol. 2016;34(36):4431-4442.

Read this lecture as Markdown